1Suzuki S, Harada N, Takeo Y, et al. Bi weekly irinotecan hydrochloride and cisplatin as a second line chemotherapy for patients with advanced gastric cancer [J]. Gan To Kagaku Ryoho, 2007,34 (13): 2245-2248.
2Shah MA,Ramanathan RK,Ilson DH,et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma [J]. J Clin Oncol,2006,24(33) :5201-5206.
3Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric esophageal gastric junction adenocarcinoma : results of a randomized phase II study[J]. Ann Oncol,2004,15(12) : 1773-1781.
4Dank M,Zaluski J,Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastricjunction[J]. Ann Oncol, 2008, 19(8): 1450- 1457.
5Souglakos J, Syrigos K, Potamianou A, et al. Combination of irinoteean (CPT 11 ) plus oxaliplatin (L-OHP) as first line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial[J]. Ann Oncol, 2004,15 (8) : 1204- 1209.
